July / August 2019


Case for consistent treatment of DR, DME

Data from clinical trials and real-world findings suggest early and regular treatment provides optimal outcomes.

Protocol V, ERM biomarker, AI and injection for GA

The case for observation in CI-DME, DRIL in ERM surgery, AI to predict HbA1c and screen for DR, and a subcutaneous mitochondrial agent.

Regression following IVT anti-VEGF in ROP

A review of disease progression patterns and the role for laser ablative therapy and intravitreal bevacizumab therapy.

The promise and pitfalls of suprachoroidal dosing

Investigational suprachoroidal delivery platforms have leveraged excellent bioavailability with favorable safety signals.

Scleral buckling surgery: As vital as ever

A review of modern techniques and indications for the repair of rhegmatogenous retinal detachments.


Clinical Trial Closeup

Modulating macrophages to target GA

Investigational candidate aims to change macrophage behavior in management of dry age-related macular degeneration.

Editor's Page

Innovation Insight

AMD is gene therapy’s emerging darling

Most programs in retinal disease still target inherited disorders, but both wet and dry forms of age-related macular degeneration are attracting interest.


Retina CEO

Arm yourself for payer negotiations

Uphill battle or slippery slope? These ideas can give you solid footing when seeking better reimbursement terms.

Surgical Pearl Video

The Yamane technique optimized

A modification of the highly regarded approach to intraocular lens scleral fixation.